Company Overview and News

0
21-year high – Hong Kong property sales expected to touch US$51 billion in first six months this year

2018-06-18 scmp
Property sales in Hong Kong are expected to touch HK$400 billion (US$50.96 billion) – a 21-year high – in the first half this year, as one after another homes, office towers and parking spaces set records in the world’s most expensive real estate market, according to Centaline Property Agency.
SUHJY 0016 SHGKF SHGKY 0012 SUHJF

0
Hong Kong homebuyers snap up flats in city’s first two sales after US interest rate increase

2018-06-16 scmp
Homebuyers in Hong Kong rushed to buy flats on Friday and Saturday in the city’s first two sales after the US raised interest rates, indicating no dip in the buoyant and expensive local property market.
0012

0
Fear of interest rates hike, high prices, hit latest property sale

2018-06-12 scmp
But still, three projects alone have pulled in US$1.46 billion worth of sales released in the past fortnight
0017 0050 0012

0
Hong Kong property giant CK Asset to redevelop Central’s Hutchison House as valuations soar

2018-06-07 scmp
Sources tell the Post the company has served notice on tenants, while analysts estimate the value of the building could triple to some US$3 billion
CKHUF CKHUY 0012

0
Henderson Land looks to farmland conversion, ageing buildings to stoke development pipeline

2018-06-02 scmp
Henderson Land Development will look to a combination of sites sold at government tender and private land acquisitions to help replenish its land bank at a time of soaring property values in Hong Kong.
HDVTY HDVTF 0097 0012

0
Henderson to buy Japanese retailer FamilyMart’s Hong Kong stores for US$38 million

2018-05-25 scmp
Property developer Henderson Land plans to acquire the Hong Kong unit of FamilyMart UNY, Japan’s second-largest convenience store chain, for HK$300 million (US$38 million) through its investment subsidiary, it announced on Thursday.
HDVTY HDVTF 0097 0012

0
Hong Kong’s record US$3.2bil land sale shows rate fear is benign

2018-05-16 thestar.com.my
Super high-end: The Kai Tak area in Kowloon has become one of Hong Kong’s hottest property markets, attracting a flock of investors in recent years. — Reuters
SUHJY 0016 SHGKF SHGKY 0086 0012 SUHJF

0
Sun Hung Kai pays HK$25.1 billion for Hong Kong’s costliest residential land at Kai Tak

2018-05-15 scmp
One of the city’s largest land owners won the 14th government tender by paying a record HK$25.1 billion for a plot with gross floor area of 1.42 million sq ft
SHGKY KRYPY 0086 LFSYF 0083 1212 0683 0012 SUHJF SUHJY 0016 SHGKF 0813 M35 SHMAY SIOPF KRYPF LFSYY

0
Kai Tak plot could fetch US$3.25 billion, smashing records for Hong Kong land sales

2018-05-11 scmp
Developers are forming consortiums to spread the financial risk of bidding for a residential site that could fetch an estimated US$3.25 billion
SHGKY KRYPY LFSYF 0083 1212 0683 0012 SUHJF SUHJY 0016 SHGKF M35 KRYPF LFSYY

12
Politics a barrier to plans to help alleviate Hong Kong’s housing shortage, tycoon Victor Li says   

2018-05-09 scmp
Hong Kong tycoon Victor Li Tzar-kuoi sees political considerations as a major barrier to a government plan for joint public and private development of agricultural land for housing, casting doubt on whether the model could help boost home affordability in the city.
SHGKY MS.PRE MS.PRF MS.PRG MS.PRA 0012 SUHJF SUHJY 0017 0016 SHGKF MS.PRI MS.PRK MS

1
Martin J. Whitman, Third Avenue Management Founder, Dies at 93 - Bloomberg

2018-04-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
TYIDF TYIDY 6201 0012 NBR

0
Developers’ hoard of empty flats aggravates Hong Kong’s housing crisis. Will a tax fix it?

2018-04-15 scmp
Close to 300 flats lie disturbingly vacant in a completed new residential development in Ho Man Tin even as the Hong Kong government struggles to resolve the perennial short supply of housing in the world’s most expensive property market.
SUHJY 0017 0016 SHGKF SHGKY KRYPY KRYPF 0012 0683 SUHJF

0
Skyrocketing home prices keep Hongkongers living in Shenzhen from moving back to city

2018-04-03 scmp
Average home prices in Shenzhen were about half of those in Hong Kong in 2017, according to data by Cushman and Wakefield
0012

0
HNA’s Hong Kong-listed subsidiary reports net profit plunged 96pc in 2017

2018-03-25 scmp
HNA Group’s Hong Kong-listed unit reported its net profit plunged 96 per cent in 2017, citing headwinds that include a sharp increase in interest expenses coupled with falling income from property development and its foundation piling business.
0012

12
Henderson Land’s underlying profit rises 38 per cent, beats estimates

2018-03-21 scmp
Lee Shau-kee’s property company reveals it has majority stakes in 51 old tenement buildings that could be redeveloped
MS.PRI HDVTY HDVTF MS.PRK 0097 MS.PRE MS.PRF MS.PRG MS MS.PRA 0012

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to HKEX:0012 / Henderson Land Development Co. Ltd on message board site Silicon Investor.

homestead #A001293 homestead #A001292
homestead #A001291 homestead #A001290
A001295 A001294